Skip to main content

Detail

Herwig P.  Moll
DI Dr. Herwig P. Moll

Center for Physiology and Pharmacology (Institute of Pharmacology)
Position: Research Associate (Postdoc)

ORCID: 40160 31344
T +43 1 40160 31344
herwig.moll@meduniwien.ac.at

Keywords

Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; CRISPR-Cas Systems; Genes, Tumor Suppressor; Immune Evasion; Immunotherapy; Inflammation; Lung; Mice, Knockout; Oncogenes

Research group(s)

Research interests

 In the focus of our research are tumor intrinsic and extrinsic events during the development of lung tumors driven by mutations in KRAS or EGFR. We aim to understand how alterations in the tumor affect the stroma and vice versa. A particular emphasis lies on the inflammatory aspect of lung tumorigenesis, as well as to identify novel therapeutic strategies to treat patients suffering from this devastating disease. To study lung tumorigenesis, we have developed and established several in vitro and in vivo models in our laboratory.

Techniques, methods & infrastructure

We use conditional mouse models for autochthonous lung tumors driven by KRAS or EGFR mutations, orthotopic transplantation models into syngeneic immunocompetent mice and/or immunodeficient mice. Furthermore we developed T cell dependent mouse models of lung tumorigenesis via overexpression of the ovalbumin antigen.

Moreover, CRISPR/Cas9 technology is well established in our laboratory to tailor human and mouse lung tumor cell lines.

Selected publications

  1. Moll, H.P. et al., 2018. Afatinib restrains K-RAS–driven lung tumorigenesis. Science Translational Medicine, 10(446), p.eaao2301. Available at: http://dx.doi.org/10.1126/scitranslmed.aao2301.
  2. Mohrherr, J. et al., 2019. JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression. International Journal of Cancer, 145(12), pp.3376–3388. Available at: http://dx.doi.org/10.1002/ijc.32624.
  3. Sdelci, S. et al., 2019. MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 51(6), pp.990–998. Available at: http://dx.doi.org/10.1038/s41588-019-0413-z.
  4. Bousquet Mur, E. et al., 2019. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Journal of Clinical Investigation, 130(2), pp.612–624. Available at: http://dx.doi.org/10.1172/jci126896.
  5. Grabner, B. et al., 2015. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications, 6(1). Available at: http://dx.doi.org/10.1038/ncomms7285.